S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
NASDAQ:OBSV

ObsEva Stock Forecast, Price & News

$1.53
-0.02 (-1.29%)
(As of 01/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.51
$1.62
50-Day Range
$1.48
$2.40
52-Week Range
$1.41
$5.55
Volume
545,993 shs
Average Volume
958,843 shs
Market Capitalization
$119.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.63
30 days | 90 days | 365 days | Advanced Chart
Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter.


ObsEva logo

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Headlines

Zacks: Brokerages Expect ObsEva SA (NASDAQ:OBSV) to Post -$0.22 EPS
January 10, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OBSV
Fax
N/A
Employees
45
Year Founded
N/A

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$0.15 per share

Profitability

Net Income
$-82.97 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$119.30 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/28/2022
Next Earnings (Estimated)
3/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

1064th out of 1,417 stocks

Pharmaceutical Preparations Industry

518th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












ObsEva (NASDAQ:OBSV) Frequently Asked Questions

Is ObsEva a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ObsEva in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ObsEva stock.
View analyst ratings for ObsEva
or view top-rated stocks.

How has ObsEva's stock price been impacted by Coronavirus?

ObsEva's stock was trading at $2.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OBSV stock has decreased by 40.5% and is now trading at $1.53.
View which stocks have been most impacted by COVID-19
.

When is ObsEva's next earnings date?

ObsEva is scheduled to release its next quarterly earnings announcement on Friday, March 4th 2022.
View our earnings forecast for ObsEva
.

How were ObsEva's earnings last quarter?

ObsEva SA (NASDAQ:OBSV) announced its earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.23.
View ObsEva's earnings history
.

What price target have analysts set for OBSV?

2 brokers have issued 12-month target prices for ObsEva's stock. Their forecasts range from $15.00 to $21.00. On average, they anticipate ObsEva's stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 1,076.5% from the stock's current price.
View analysts' price targets for ObsEva
or view top-rated stocks among Wall Street analysts.

Who are ObsEva's key executives?

ObsEva's management team includes the following people:
  • Brian O'Callaghan, Chief Executive Officer & Director
  • William M. Brown, Chief Financial Officer
  • Jean-Pierre Gotteland, Chief Scientific Officer, Head-R&D
  • Elizabeth Ijeoma Onyemelukwe Garner, Chief Medical Officer
  • Elke Bestel, VP, Head-Drug Safety & Pharmacovigilance

What other stocks do shareholders of ObsEva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ObsEva investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Trevena (TRVN), Zosano Pharma (ZSAN), Vaxart (VXRT), VBI Vaccines (VBIV), Bionano Genomics (BNGO) and ADMA Biologics (ADMA).

When did ObsEva IPO?

(OBSV) raised $98 million in an IPO on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is ObsEva's stock symbol?

ObsEva trades on the NASDAQ under the ticker symbol "OBSV."

Who are ObsEva's major shareholders?

ObsEva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.04%).

Which institutional investors are selling ObsEva stock?

OBSV stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of ObsEva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ObsEva's stock price today?

One share of OBSV stock can currently be purchased for approximately $1.53.

How much money does ObsEva make?

ObsEva has a market capitalization of $119.30 million and generates $20 thousand in revenue each year. The company earns $-82.97 million in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does ObsEva have?

ObsEva employs 45 workers across the globe.

What is ObsEva's official website?

The official website for ObsEva is www.obseva.com.

Where are ObsEva's headquarters?

How can I contact ObsEva?

ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at (122) 552-3840 or via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.